Tempramed Technologies releases VIVI Med

Executive Summary

• Tempramed Technologies Ltd. has commercially launched "VIVI Med," a new temperature-protection solution designed to safeguard medication vials, biologics, and other critical therapies outside the standard insulin-pen format.
• The launch represents a strategic expansion of the company's addressable market, targeting high-value biologics (such as Humira), GLP-1 receptor agonists, insulin vials, and temperature-sensitive blood glucose test strips.
• VIVI Med utilizes the company's proprietary, patented passive thermal-protection technology to provide 24/7/365 protection without batteries, charging, or maintenance, targeting consumer, B2B, and healthcare-system channels.

Key Details

• Product Name: VIVI Med.
• Target Medications: Medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips.
• Technology Features:
  • Provides year-round temperature protection without refrigeration, electricity, or maintenance.
  • Portable, lightweight, and reusable design suitable for daily use, travel, and outdoor environments.
  • Durable, long-life construction built with space-grade materials engineered for years of repeated use.
• Strategic Context:
  • Expands Tempramed's portfolio from focusing primarily on insulin pens and epinephrine auto-injectors to a multiformat temperature-protection platform.
  • Current portfolio now includes:
    • VIVI Cap and VIVI Cap Smart (for insulin pens and certain GLP-1 pens).
    • VIVI Epi (for epinephrine auto-injectors).
    • VIVI Med (for vials, biologics, GLP-1 pens, test strips, and broader injectable formats).
• Market Opportunity: Addresses the growing global use of biologics, GLP-1 therapies, and specialty injectables for chronic, autoimmune, and metabolic conditions.

Notable Quotes

• "To date, our product portfolio has focused on insulin pens and epinephrine auto-injectors, but the medication landscape is evolving rapidly," said Ron Nagar, chief executive officer of Tempramed. "VIVI Med is a strategic expansion of our platform that allows us to address a much broader universe of temperature-sensitive medications, many of which are high-value biologics with growing patient populations. This product materially expands our addressable market and creates new opportunities across consumer, B2B and health-care-system channels. Using our proprietary, patented technology, we will continue to expand our product portfolio with new products, new applications and new markets."